Cargando…

Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017)

PURPOSE: The goal of this study was to investigate the Liver Imaging Reporting and Data System (LI-RADS) v.2017 for the categorization of hepatocellular carcinomas (HCCs) with gadoxetic acid compared with gadopentetate dimeglumine-enhanced 1.5-T magnetic resonance imaging (MRI). MATERIAL AND METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Ying, Rao, Sheng-xiang, Wang, Wen-tao, Chen, Cai-zhong, Li, Ren-chen, Zeng, Mengsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286579/ https://www.ncbi.nlm.nih.gov/pubmed/30526674 http://dx.doi.org/10.1186/s40644-018-0183-3

Ejemplares similares

Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection: prospective crossover study at 3 T
por: Besa, Cecilia, et al.
Publicado: (2015)

Comparison of Gadopentetate dimeglumine and Gadobenate dimeglumine in depiction of non-ischemic fibrosis in hypertrophic cardiomyopathy
por: Rudolph, Andre, et al.
Publicado: (2009)

Neurotoxic Manifestations of an Overdose Intrathecal Injection of Gadopentetate Dimeglumine
por: Park, Kwan-Woong, et al.
Publicado: (2010)

Single dose gadobenate dimeglumine for imaging chronic of myocardial infarction in comparison to double dose gadopentetate dimeglumine
por: Bauner, Kerstin U, et al.
Publicado: (2009)

A case report of gadopentetate dimeglumine‐induced cardiac arrest: Resuscitation using extracorporeal membrane oxygenation
por: Fang, Honglong, et al.
Publicado: (2023)

Correlations from gadopentetate dimeglumine-enhanced magnetic resonance imaging after methotrexate chemotherapy for hemorrhagic placenta increta
por: Wehbe, Salim A, et al.
Publicado: (2003)

Gadolinium Retention and Clearance in the Diabetic Brain after Administrations of Gadodiamide, Gadopentetate Dimeglumine, and Gadoterate Meglumine in a Rat Model
por: Wang, Shu-ting, et al.
Publicado: (2019)

CEMRA in neonatal and pediatric congenital vascular diseases at 1.5T and 3.0T: comparison of an intravascular contrast agent (Gadofosveset) with an extracellular agent (Gadopentetate Dimeglumine)
por: Khan, SN, et al.
Publicado: (2013)

CEMRA in neonatal and pediatric congenital vascular diseases at 1.5T and 3.0T: comparison of an intravascular contrast agent (Gadofosveset) with an extracellular agent (Gadopentetate Dimeglumine)
por: Khan, Sarah N, et al.
Publicado: (2013)

A Semi-Automatic Step-by-Step Expert-Guided LI-RADS Grading System Based on Gadoxetic Acid-Enhanced MRI
por: Sheng, Ruofan, et al.
Publicado: (2021)

Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
por: Zhang, Tong, et al.
Publicado: (2019)

Lack of nephrotoxicity of gadopentetate dimeglumine-enhanced non-vascular MRI and MRI without contrast agent in patients at high-risk for acute kidney injury
por: Oguz, Ebru Gok, et al.
Publicado: (2013)

Gadoxetic Acid (Gd-EOB-DTPA)-Enhanced MRI versus Gadobenate Dimeglumine (Gd-BOPTA)-Enhanced MRI for Preoperatively Detecting Hepatocellular Carcinoma: an Initial Experience
por: Park, Yulri, et al.
Publicado: (2010)

CT/MRI LI-RADS version 2018 versus CEUS LI-RADS version 2017 in the diagnosis of primary hepatic nodules in patients with high-risk hepatocellular carcinoma
por: Lv, Kun, et al.
Publicado: (2021)

LI-RADS category 5 hepatocellular carcinoma: preoperative gadoxetic acid–enhanced MRI for early recurrence risk stratification after curative resection
por: Wei, Hong, et al.
Publicado: (2020)

Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoxetic Acid-Enhanced MRI
por: Moon, Ji Yoon, et al.
Publicado: (2021)

Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS
por: Hu, Yi-Xin, et al.
Publicado: (2021)

Gadoxetic acid–enhanced MRI with a focus on LI-RADS v2018 imaging features predicts the prognosis after radiofrequency ablation in small hepatocellular carcinoma
por: Wang, Ruizhi, et al.
Publicado: (2023)

MR Features Based on LI-RADS Ver. 2018 Correlated with Cytokeratin 19 Expression in Combined Hepatocellular Carcinoma-Cholangiocarcinoma
por: Zhou, Changwu, et al.
Publicado: (2021)

Diagnostic accuracy of gadoxetic acid-enhanced MR for small hypervascular hepatocellular carcinoma and the concordance rate of Liver Imaging Reporting and Data System (LI-RADS)
por: Bae, Jae Seok, et al.
Publicado: (2017)

Peritumoral Dilation Radiomics of Gadoxetate Disodium-Enhanced MRI Excellently Predicts Early Recurrence of Hepatocellular Carcinoma without Macrovascular Invasion After Hepatectomy
por: Chong, Huanhuan, et al.
Publicado: (2021)

CEUS LI-RADS for diagnosis of hepatocellular carcinoma in individuals without LI-RADS-defined hepatocellular carcinoma risk factors
por: Huang, Zhe, et al.
Publicado: (2023)

Diagnostic Efficacy and Safety of Gadoxetate Disodium vs Gadobenate Dimeglumine in Patients With Known or Suspected Focal Liver Lesions: Results of a Clinical Phase III Study
por: Zech, Christoph J, et al.
Publicado: (2019)

CT/MRI LI-RADS v2017 – review of the guidelines
por: Rosiak, Grzegorz, et al.
Publicado: (2018)

CT/MRI LI-RADS v2018 vs. CEUS LI-RADS v2017—Can Things Be Put Together?
por: Caraiani, Cosmin, et al.
Publicado: (2021)

Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018
por: Lee, Sang Min, et al.
Publicado: (2021)

Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI
por: Youn, Seo Yeon, et al.
Publicado: (2021)

Utilization of a Machine Learning Algorithm for the Application of Ancillary Features to LI-RADS Categories LR3 and LR4 on Gadoxetate Disodium-Enhanced MRI
por: Park, Seongkeun, et al.
Publicado: (2023)

Severe Adverse Drug Reaction to Gadobenate Dimeglumine
por: Singer, Benjamin D., et al.
Publicado: (2009)

Differentiation between combined hepatocellular cholangiocarcinoma and hepatocellular carcinoma: comparison of diagnostic performance between ultrasomics-based model and CEUS LI-RADS v2017
por: Li, Chao-qun, et al.
Publicado: (2022)

CT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners
por: Patella, Francesca, et al.
Publicado: (2018)

LI-RADS v2017 for liver nodules: how we read and report
por: Schima, Wolfgang, et al.
Publicado: (2018)

Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma
por: Li, Yueming, et al.
Publicado: (2021)

Correction to: Differentiation between combined hepatocellular cholangiocarcinoma and hepatocellular carcinoma: comparison of diagnostic performance between ultrasomics-based model and CEUS LI-RADS v2017
por: Li, Chao-qun, et al.
Publicado: (2022)

The Unusual Suspect: Gadobenate-Dimeglumine Induced Kounis Syndrome
por: Choudhry, Faiza, et al.
Publicado: (2019)

Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma
por: Ricke, Jens, et al.
Publicado: (2020)

Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma
por: Moura Cunha, Guilherme, et al.
Publicado: (2021)

Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS
por: Cannella, Roberto, et al.
Publicado: (2021)

Modified CEUS LI-RADS using Sonazoid for the diagnosis of hepatocellular carcinoma
por: Sugimoto, Katsutoshi, et al.
Publicado: (2023)

Risk Stratification and Distribution of Hepatocellular Carcinomas in CEUS and CT/MRI LI-RADS: A Meta-Analysis
por: Zhou, Yan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_46aigcgkj4rabishl0c5rkuoug